Yingdan Cao

Economic Evaluation of Sintilimab Plus Bevacizumab Versus Sorafenib as a First-line Treatment for Unresectable Hepatocellular Carcinoma

Ting Zhou, Yingdan Cao, Xintian Wang et al. · Advances in Therapy · 2022 · 34 citations

Pharmacy, Oncology, Pharmacotherapy +14

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma

Ting Zhou, Xintian Wang, Yingdan Cao et al. · BMC Health Services Research · 2022 · 28 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +15

Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2– Advanced or Metastatic Breast Cancer: A US Payer Perspective

Yingcheng Wang, Mingjun Rui, Xin‐Yuan Guan et al. · Frontiers in Medicine · 2021 · 24 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +15

Establishment of experimental autoimmune prostatitis model by T₂peptide in aluminium hydroxide adjuvant

Li’ao Zhang, Awais Ullah Ihsan, Yingdan Cao et al. · Andrologia · 2017 · 19 citations

Medicine, Immunology, Urology +16

The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China

Rui Meng, Yingdan Cao, Ting Zhou et al. · Frontiers in Public Health · 2022 · 18 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +17